Aphria Stock Forecast, Price & News

Aphria (TSE:APHA) Frequently Asked Questions

Is Aphria a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aphria in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Aphria stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in APHA, but not buy additional shares or sell existing shares.
View analyst ratings for Aphria or view top-rated stocks.

What price target have analysts set for APHA?

6 analysts have issued 1-year target prices for Aphria's shares. Their forecasts range from C$10.75 to C$28.00. On average, they expect Aphria's share price to reach C$18.34 in the next twelve months.
View analysts' price targets for Aphria or view top-rated stocks among Wall Street analysts.

Who are Aphria's key executives?

Aphria's management team includes the following people:

• Mr. Irwin D. Simon, CEO & Chairman (Age 62, Pay $6.54M)
• Mr. Carl A. Merton, Chief Financial Officer
• Dr. Christelle Gedeon L.L.B., Ph.D., Chief Legal Officer & Corp. Sec.
• Mr. James R. Meiers, Chief Operating Officer of Aphria Leamington
• Ms. Denise Menikheim Faltischek, Chief Strategy Officer & MD of Aphria Germany (Age 48, Pay $562.35k)
• Mr. John B. Sadler, VP of Investor Relations
• Mr. Bernard Yeung, Sr. VP of Sales & Marketing
• Mr. Victor Neufeld, Special Advisor (Age 67)
• Mr. Cole Cacciavillani, Special Advisor (Age 66)
• Mr. Randy Daigneau, Sr. VP of Supply Chain

Who are some of Aphria's key competitors?

Some companies that are related to Aphria include Bausch Health Companies (BHC), Valeant Pharmaceuticals International (VRX), Evotec (EVT), Hikma Pharmaceuticals (HIK), Canopy Growth (WEED), Aurora Cannabis (ACB), Hydropothecary (THCX), OrganiGram (OGI), Knight Therapeutics (GUD), HLS Therapeutics (HLS), Amryt Pharma (AMYT), Benchmark (BMK), HEXO (HEXO), Supreme Cannabis (FIRE) and ESSA Pharma (EPI).
View all of APHA's competitors.

What other stocks do shareholders of Aphria own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aphria investors own include Aurora Cannabis (ACB), Canopy Growth (WEED), (CGC), Aurora Cannabis (ACB), OrganiGram (OGI), KushCo (KSHB), NVIDIA (NVDA), CannTrust (CTST), Cronos Group (CRON) and Cronos Group (CRON).

What is Aphria's stock symbol?

Aphria trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APHA."

How do I buy shares of Aphria?

Shares of APHA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

How much money does Aphria make?

Aphria has a market capitalization of C$0.00 and generates C$611.06 million in revenue each year.

How many employees does Aphria have?

Aphria employs 1,200 workers across the globe.

What is Aphria's official website?

The official website for Aphria is www.aphria.com.

Where are Aphria's headquarters?

Aphria is headquartered at 245 Talbot St W Suite 103, LEAMINGTON, ON N8H 1N8, Canada.

How can I contact Aphria?

Aphria's mailing address is 245 Talbot St W Suite 103, LEAMINGTON, ON N8H 1N8, Canada. The company can be reached via phone at 844-427-4742.